Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 30;14(4):e2024259.
doi: 10.5826/dpc.1404a259.

Impact of Xerosis in Patients with Cancer Receiving Epidermal Growth Factor Receptor or Mitogen-Activated Protein Kinase Inhibitors: ATIXI, A Non-Interventional Prospective Pilot Study

Pietro Quaglino  1 , Giuseppe Argenziano  2 , Emi Dika  3   4 , Michela Starace  4   5 , Simone Amabile  1 , Paolo Fava  1 , Elvira Moscarella  2 , Bianca Maria Piraccini  4   5 , Alain Delarue  6 , Olivia Dialla  7 , Fabienne Zumaglini  6 , Giampiero Girolomoni  8
Affiliations

Impact of Xerosis in Patients with Cancer Receiving Epidermal Growth Factor Receptor or Mitogen-Activated Protein Kinase Inhibitors: ATIXI, A Non-Interventional Prospective Pilot Study

Pietro Quaglino et al. Dermatol Pract Concept. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing Interests: PQ has received advisory board and speaker fees from Novartis and Pierre-Fabre. AD, OD and FZ are employees of Pierre Fabre. GA, ED, MS, SA, PF, EM, BMP have no conflicts of interest to declare. GG has received personal fees from AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Leo Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung Bioepis and Sanofi.

Figures

Figure 1
Figure 1
Number of patients who attended all three study visits with emerging or worsening xerosis while receiving epidermal growth factor receptor or mitogen-activated protein kinase inhibitors (n=22).
See this image and copyright information in PMC

References

    1. Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl 1):31–9. doi: 10.1007/s40257-018-0384-3. - DOI - PMC - PubMed
    1. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491–500. doi: 10.1016/S1470-2045(05)70243-6. - DOI - PubMed
    1. Valentine J, Belum VR, Duran J, et al. Incidence and risk of xerosis with targeted anticancer therapies. J Am Acad Dermatol. 2015;72(4):656–667. doi: 10.1016/j.jaad.2014.12.010. - DOI - PubMed
    1. Lee J, Lim J, Park JS, et al. The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study. Cancer Res Treat. 2018;50(4):1186–1193. doi: 10.4143/crt.2017.435. - DOI - PMC - PubMed
    1. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803–812. doi: 10.1038/nrc1970. - DOI - PubMed

LinkOut - more resources